Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Frequently asked questions
What sector does Absci Corp (ABSI) operate in?
Absci Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Absci Corp (ABSI) current stock price?
As of the latest data, Absci Corp stock price is $9.65, with a previous close of $9.27. Absci Corp gained $0.38 in the last trading session, representing a 4.1% increase.
What is Absci Corp (ABSI) current market capitalization?
Absci Corp market cap is approximately 1.66 billion.
What is Absci Corp (ABSI) Earnings Per Share (EPS)?
The trailing EPS is -$0.77, and the forward EPS is -$0.68.
What is Absci Corp (ABSI) EBITDA?
Absci Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -30.47 million.
Does Absci Corp (ABSI) pay dividends?
No. Absci Corp does not pay a dividend.
How did Absci Corp (ABSI) perform in its most recent earnings report?
In the last report (June 30, 2026), Absci Corp posted an EPS surprise of -5% and a revenue surprise of -65.87%.
What is Absci Corp (ABSI) beta (volatility) score?
Absci Corp has a beta of 2.436, indicating very high volatility compared to the market.
